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Understanding Role of NK Cells in Uterine
Cancers
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LSUHSC New Orleans, Section of surgical oncology, Louisiana Children's Medical Center Cancer Center

NK cell in homeostasis

Introduction

NK cell in uterine cancer environment

Cancer is one of the major health problem in the modern world. The
incident of cancer is dependent on several factors, such as gender,
genetics, immune status, and other environmental factors. Specifically,
uterine cancers, which include endometrial cancer (EC) and cervical
cancer (CC) are the most prevalent gynecologic malignancies amongst
American women. About 83% of uterine cancer cases are
endometrioid carcinomas, while fewer than 10% are sarcomas.
Furthermore, the incidence of EC has continually increased over the
past few decades. As of 2019, the rate of new uterine cancer cases is
28.4% with a 5.1% death rate and the 5-year relative survival from
2012 to 2018 is 81.3%.
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Figure 1. Incidence and mortality due to uterine cancer over past 30
years.

The role of the immune system in cancer pathogenesis, including uterine
cancer is well established. However, not much is known about the role of NK
cells in uterine cancer pathogenesis, which is the focus of this paper.
Nowadays NK cell-based immunotherapy are emerging, due to their cytotoxic
actions on cancer cells. The table below shows the dysregulated NK cells
governing their immune function in the uterine cancer tumor immune
microenvironment (TIME).
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Figure 2. Different stages of uterine caner within 5-year relative
survival.
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Figure 3. Immune environment in female reproductive tract.

Future perspective and conclusion

Inhibitory
KIR2DL1,2,3
KIR2DL5
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2B4 (both of these are activating or
inhibitory, depending on stage)
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Figure 4. Impact of immunosuppressive environment on NK function and
number. Increase in immunosuppressive cells (M2 macrophages and myeloid
derived suppressor cell on uterine tumor causes the release of
immunosuppressive molecules. This subsequently causes decrease in NK cell
number and function downstream.
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Future uterine cancer treatment immunotherapy options ought to leverage the
cytotoxic functions of NK cells to create more targeted cellular responses. For
example, NK cell inhibitory receptors that are upregulated in uterine cancer
such as NKG2A, KLRG1, PD-1, and TIGIT, can be helpful targets when
devising an immunotherapeutic option for uterine cancer. Target based
therapies, including NK cell based ones, may also increase the quality of life
with less side effects. For example, allogenic NK cell therapy does not include
the side effect of graft-versus host disease. Therefore, the development of
novel NK cell targeted treatments are essential in creating more robust cures
for uterine cancer.
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